The special series “New Era of Treatment for Unresectable Locally Advanced Non-Small Cell Lung Cancer” of TLCR was guest-edited by Prof. Zhengfei Zhu from Fudan University Shanghai Cancer Center (China), Prof. Xiaolong Fu from Shanghai Chest Hospital (China) and Prof. Steven H. Lin from the University of Texas MD Anderson Cancer Center (USA).
Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?
Is clinical target volume necessary?—a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique
Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy
Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients
Optimizing current standard of care therapy for stage III non-small cell lung cancer
A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy
Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review
Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review
GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
Disclosure:
The series “New Era of Treatment for Unresectable Locally Advanced Non-Small Cell Lung Cancer” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. SHL served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of Translational Lung Cancer Research from Sept 2019 to Sept 2021. ZFZ and XLF served as the unpaid Guest Editors of the series.